Bristol Myers Squibb (NYSE:BMY) Earns Buy Rating from Guggenheim

Bristol Myers Squibb (NYSE:BMY)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a report released on Wednesday,Benzinga reports. They presently have a $72.00 price target on the biopharmaceutical company’s stock. Guggenheim’s target price indicates a potential upside of 24.82% from the stock’s current price.

Several other research analysts have also commented on the company. Wells Fargo & Company restated an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their target price for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Finally, Piper Sandler reiterated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $61.35.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $57.68 on Wednesday. The firm has a 50-day simple moving average of $59.51 and a two-hundred day simple moving average of $52.94. The stock has a market cap of $117.77 billion, a PE ratio of 16.72, a P/E/G ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the previous year, the business posted $1.67 EPS. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current year.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds have recently made changes to their positions in the company. J. Derek Lewis & Associates Inc. purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $432,000. Osbon Capital Management LLC acquired a new position in Bristol Myers Squibb during the fourth quarter worth approximately $55,000. World Investment Advisors boosted its holdings in shares of Bristol Myers Squibb by 14.1% in the fourth quarter. World Investment Advisors now owns 64,471 shares of the biopharmaceutical company’s stock valued at $3,478,000 after acquiring an additional 7,977 shares during the period. Nalls Sherbakoff Group LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $92,000. Finally, Larry Mathis Financial Planning LLC acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $427,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.